A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLS31903 in Advanced Solid Tumor Patients

Recruiting now · Phase 1

Conditions studied: Advanced Solid Tumors

In brief

The purpose of the study is to evaluate safety, pharmacokinetics,immunogenicity and efficacy of QLS31903 alone in the treatment of advanced cancer.

Key facts

Study ID

NCT05823285

Run by

Qilu Pharmaceutical Co., Ltd.

People needed

150

Starts

2023-03-22

Expected to finish

2027-06-15

Last updated by the study team

2023-04-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Fudan Zhongshan Hospital — Shanghai, Shanghai Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.